miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells

Ruey-Jen Lin1, You-Chin Lin, Alice L Yu

  • 1Graduate Institute of Life Science, National Defense Medical Center, Taipei, Taiwan.

Insights

MicroRNAs (miRNAs) regulate gene expression. This study reveals miR-149* directly targets Akt1 and E2F1, inducing apoptosis in neuroblastoma cells, and suggests miR-149* has anti-cancer potential.

Area of Science:

  • Molecular Biology
  • Gene Regulation
  • Cancer Biology

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression, influencing processes like apoptosis.
  • The Akt signaling pathway is crucial for cell survival, but its regulation by miRNAs is not fully understood.
  • Akt1 is the predominant isoform, and its direct targeting by miRNAs remains to be elucidated.

Purpose of the Study:

  • To investigate whether Akt1 is a direct target of microRNA.
  • To identify novel targets of miR-149* and elucidate its role in apoptosis.
  • To explore the therapeutic potential of miR-149* in neuroblastoma.

Main Methods:

  • Reporter assays to confirm direct miRNA targeting.
  • Western blot analysis to assess protein expression changes.
  • Ectopic expression and silencing of miRNAs and target genes in cell lines.

Main Results:

  • Akt1 and E2F1 were identified as direct targets of miR-149*.
  • miR-149* expression induced apoptosis in neuroblastoma and HeLa cells.
  • Silencing Akt1 or E2F1 mimicked the pro-apoptotic effects of miR-149*.
  • A significant inverse correlation between miR-149* and E2F1 was observed in neuroblastoma samples.

Conclusions:

  • Akt1 is a direct miRNA target, expanding the understanding of miRNA regulatory networks.
  • miR-149* acts as a pro-apoptotic miRNA by repressing Akt1 and E2F1.
  • miR-149*'s pro-apoptotic function is not inhibited by miR-149 in vivo.
  • miR-149* demonstrates potential as a therapeutic agent against neuroblastoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...